Journal of Systems Biology & Proteome Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-7360-538437

Editorial - Journal of Systems Biology & Proteome Research (2022) Volume 3, Issue 5

Mouse embryos that have been given histone deacetylase and dna methyltransferase inhibitors

Widespread clinical use of the recently approved medications 5-azacitidine and 5-aza-2- deoxyazacytidine is being made to treat all forms of myelodysplastic syndrome as well as chronic myelomonocytic leukaemia. These medications have been tested in randomised clinical trials that show response rates in patients for whom there was no prior standard of care, and they were designed based on an awareness of the significance of epigenetic modifications in malignancy. We are able to target additional chromatin conformation regulators that contribute to aberrant gene transcription and dysregulated cell development as our knowledge of the epigenetic alterations typical of the malignant phenotype advances. One class of medications created utilising this approach is the histone deacetylase inhibitors. Although therapeutic trials utilising HDAC inhibitors in combination with DNA methyltransferase inhibitors have shown promising results, responses using HDAC inhibitors alone in myelodysplastic syndrome have been minimal. Combination therapy gives myelodysplastic patients with previously incurable disease the chance for hematologic improvement and remission. We also give illustrations of how variations in these epigenetic variables impact mouse and human early development. In conclusion, this review offers a synopsis of the most significant epigenetic mechanisms and instances of the tremendous impacts of epigenetic alterations on early mammalian development.

Author(s): Mario Niklas

Abstract Full Text PDF

Get the App